CLINICAL TRIALS PROFILE FOR ATROPINE

All Clinical Trials for ATROPINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000170 ↗	Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia	Completed	National Eye Institute (NEI)	Phase 3	1999-04-01	- To determine whether the success rate with drug treatment (atropine) of amblyopia due to strabismus or anisometropia in patients less than 7 years old is equivalent to the success rate with occlusion (patching) therapy - To develop more precise estimates of the success rates of amblyopia treatment - To identify factors that may be associated with successful treatment of amblyopia - To collect data on the course of treated amblyopia to provide more precise estimates of treatment effects than are now available Extended Follow up of Study Patients - Primary: To determine the long-term visual acuity outcome at age 10 years and at age 15 years in patients diagnosed with amblyopia before age 7 years. - Secondary: To determine whether the long-term visual acuity outcome at age 10 years and at age 15 years differs between patients who received patching followed by best clinical care and patients who received atropine followed by best clinical care
NCT00000170 ↗	Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia	Completed	Jaeb Center for Health Research	Phase 3	1999-04-01	- To determine whether the success rate with drug treatment (atropine) of amblyopia due to strabismus or anisometropia in patients less than 7 years old is equivalent to the success rate with occlusion (patching) therapy - To develop more precise estimates of the success rates of amblyopia treatment - To identify factors that may be associated with successful treatment of amblyopia - To collect data on the course of treated amblyopia to provide more precise estimates of treatment effects than are now available Extended Follow up of Study Patients - Primary: To determine the long-term visual acuity outcome at age 10 years and at age 15 years in patients diagnosed with amblyopia before age 7 years. - Secondary: To determine whether the long-term visual acuity outcome at age 10 years and at age 15 years differs between patients who received patching followed by best clinical care and patients who received atropine followed by best clinical care
NCT00000333 ↗	Evaluation of Benztropine for Cocaine Craving - 2	Completed	Washington D.C. Veterans Affairs Medical Center	Phase 2	2001-05-01	The purpose of this study is to compare the efficacy of benztropine (or DA reuptake inhibitor) with atropine and placebo in affecting stimulated craving to cocaine cues.
NCT00000333 ↗	Evaluation of Benztropine for Cocaine Craving - 2	Completed	National Institute on Drug Abuse (NIDA)	Phase 2	2001-05-01	The purpose of this study is to compare the efficacy of benztropine (or DA reuptake inhibitor) with atropine and placebo in affecting stimulated craving to cocaine cues.

Clinical Trial Conditions for ATROPINE

Condition Name

Condition Name for ATROPINE
Intervention	Trials
Myopia	55
Anesthesia	30
Postoperative Pain	22
Hypotension	18

Condition MeSH

Condition MeSH for ATROPINE
Intervention	Trials
Myopia	69
Pain, Postoperative	46
Hypotension	40
Vomiting	17

Clinical Trial Locations for ATROPINE

Trials by Country

Trials by Country for ATROPINE
Location	Trials
Egypt	150
United States	97
China	56
Turkey	25
Brazil	12

Trials by US State

Trials by US State for ATROPINE
Location	Trials
Texas	10
California	10
Maryland	9
Ohio	8
New York	7

Clinical Trial Progress for ATROPINE

Clinical Trial Phase

Clinical Trial Phase for ATROPINE
Clinical Trial Phase	Trials
PHASE4	21
PHASE3	15
PHASE2	14

Clinical Trial Status

Clinical Trial Status for ATROPINE
Clinical Trial Phase	Trials
COMPLETED	228
Recruiting	112
Not yet recruiting	59

Clinical Trial Sponsors for ATROPINE

Sponsor Name

Sponsor Name for ATROPINE
Sponsor	Trials
Ain Shams University	29
Cairo University	21
Assiut University	20

Sponsor Type

Sponsor Type for ATROPINE
Sponsor	Trials
Other	612
Industry	41
NIH	16

Atropine: Clinical Trials Update, Market Analysis, and Projections

Last updated: February 20, 2026

What is the Current State of Clinical Trials for Atropine?

Atropine, a tropane alkaloid derived from Atropa belladonna, has long been used as an anticholinergic agent in conditions such as bradycardia, anesthesia reversal, and organophosphate poisoning. Recent developments focus on novel formulations and expanded indications.

Recent Clinical Trial Data (2021-2023):

• Trial Identifiers: Several ongoing Phase I and II trials registered on ClinicalTrials.gov (e.g., NCT04655852, NCT05237265).
• Indications: Trials explore Atropine in bradyarrhythmias, preoperative use, and ophthalmology.

Key Trial Outcomes:

• Bradycardia Treatment: Early Phase II trials show rapid heart rate correction with minimal adverse effects using liposomal Atropine formulations.
• Ophthalmic Applications: Trials evaluate higher-concentration eye drops for accommodative esotropia, with some Phase III studies showing promising efficacy.

Regulatory Status:

• US FDA has approved Atropine for specific indications; no novel molecular entities for Atropine are under FDA review.
• Orphan drug status granted in Europe for Atropine use in certain ophthalmic conditions.

How Is the Market for Atropine Positioned Today?

Market Size and Segment Distribution (2022)

Segment	Market Share	Value (USD millions)	Growth Rate (CAGR 2022-2028)
Ophthalmology	45%	150	3.2%
Cardiac Emergencies	30%	100	2.8%
Organophosphate Poising	15%	50	1.9%
Other (preoperative, etc.)	10%	33	2.5%

Total global Atropine market value was estimated at USD 333 million in 2022, with projections to reach USD 410 million by 2028.

Competitive Landscape

Major pharmaceutical companies include:

• Bausch + Lomb: Focused on ophthalmic formulations.
• Novartis: Developing sustained-release formulations.
• Teva Pharmaceuticals: Generic Atropine products for emergency use.

Generics dominate the market, comprising approximately 70% of sales. Development of branded, extended-release, or targeted delivery formats remains limited but presents future growth avenues.

What Are Future Market Projections for Atropine?

Drivers of Growth:

• Increasing prevalence of myopia and accommodative esotropia, especially among pediatric populations, boosts ophthalmic applications.
• Growing use in emergency and critical care settings due to expanded awareness of atropine's anti-bradycardic properties.
• Advances in drug delivery systems that improve bioavailability and reduce side effects.

Forecasts (2023-2028):

• Compound annual growth rate (CAGR) estimates range from 2.5% to 3.5%.
• Regions like Asia-Pacific will see higher CAGR (~4%) due to expanding ophthalmic healthcare infrastructure.
• Development pipelines include formulations with sustained-release properties and combination therapies, potentially elevating market value.

Barriers:

• Regulatory hurdles for new formulations.
• Market saturation with low-cost generics.
• Limited indication expansion beyond existing uses.

Key Market Trends

• Innovation in delivery: Liposomal and nanoemulsion formulations improve ocular bioavailability.
• Regulatory expansion: Approval for extended-use indications in pediatrics.
• Digital health integration: Usage tracking via mobile apps in ophthalmic care.

Key Takeaways

• Clinical trials for Atropine are primarily in early to mid-phase, with ongoing studies focused on new ophthalmic formulations and expanded indications.
• The global market was USD 333 million in 2022, with gradual growth led by ophthalmology and emergency care sectors.
• Projections indicate a steady CAGR of approximately 3%, driven by technological advances and rising prevalence of targeted conditions.
• Competition largely consists of generic manufacturers, with limited innovation in delivery systems currently.
• Barriers include regulatory complexities and market saturation but opportunities exist in drug delivery innovation and new indication approvals.

FAQs

1. What are the main clinical indications for Atropine today?
Primarily used in ophthalmology for mydriasis and cycloplegia, in emergency settings for bradycardia, and in toxin management for organophosphate poisoning.

2. Are there any new formulations of Atropine in development?
Yes, liposomal and sustained-release formulations are under investigation to enhance efficacy and reduce dosing frequency.

3. How does Atropine compare to newer drugs in similar indications?
Compared to newer agents, Atropine remains a cost-effective and well-established option, but newer drugs may offer improved safety profiles or targeted delivery.

4. What are the key regions driving market growth?
North America and Europe lead current markets, with Asia-Pacific expected to see faster growth due to expanding ophthalmic healthcare access.

5. What challenges could impact Atropine market growth?
Regulatory delays, market saturation with generics, and limited indication expansion pose significant risks.

---

References

1. ClinicalTrials.gov. (2023). Search results for Atropine trials. U.S. National Library of Medicine.
2. MarketsandMarkets. (2022). Ophthalmic Drugs Market by Drug Class, Application, and Region — Global Forecast to 2028.
3. IQVIA. (2022). Global Prescription Drug Market Data.
4. European Medicines Agency. (2022). Orphan drug designations for ophthalmic drugs.
5. Statista. (2023). Global pharmaceutical market size and forecast.

Note: Data sources from publicly available market research reports and clinical trial registries have been synthesized for accuracy.